| dc.contributor.author | Perry, Mandy | en |
| dc.contributor.author | McDonald, Timothy J. | en |
| dc.contributor.author | Cudmore, Adrian | en |
| dc.contributor.author | Ahmad, Tariq | en |
| dc.date.accessioned | 2016-08-08T11:50:02Z | |
| dc.date.available | 2016-08-08T11:50:02Z | |
| dc.date.issued | 2015-11-02 | |
| dc.identifier.citation | Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis. 2015. Clinical Laboratory International | en |
| dc.identifier.uri | http://hdl.handle.net/11287/618029 | |
| dc.description.abstract | The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is associated with production of antibodies to the therapy. Measuring trough drug and antibody concentrations may direct patient management in future. | en |
| dc.language.iso | en | en |
| dc.publisher | Clinical Laboratory International | en |
| dc.relation.url | http://www.cli-online.com/index.php?id=4173 | en |
| dc.subject | Wessex Classification Subject Headings::Gastroenterology | en |
| dc.title | Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis | en |
| dc.type | Journal Article | en |
| dc.identifier.journal | Clinical Laboratory International | en |
| dc.type.version | Published | en |
